Insider · CIK 0001303417
Deirdre P Connelly
director
Files at LNC (LINCOLN NATIONAL CORP), M (Macy's, Inc.), SRPT (Sarepta Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | LNC LINCOLN NATIONAL CORP | AGrant or award Phantom Stock Unitderivative | +1,118 | $40.26 | $45k | 50,661 | 10 d ago |
| Dec 31, 2025 | LNC LINCOLN NATIONAL CORP | AGrant or award Phantom Stock Unitderivative | +1,011 | $44.53 | $45k | 45,474 | Jan 5, 2026 |
| Sep 30, 2025 | LNC LINCOLN NATIONAL CORP | AGrant or award Phantom Stock Unitderivative | +1,116 | $40.33 | $45k | 43,977 | Oct 2, 2025 |
| Jun 30, 2025 | LNC LINCOLN NATIONAL CORP | AGrant or award Phantom Stock Unitderivative | +1,301 | $34.60 | $45k | 42,344 | Jul 2, 2025 |
| May 30, 2025 | M Macy's, Inc. | AGrant or award Restricted Stock Unitsderivative | +13,456 | $0.00 | $0 | 13,456 | Jun 3, 2025 |
| Mar 31, 2025 | LNC LINCOLN NATIONAL CORP | AGrant or award Phantom Stock Unitderivative | +1,253 | $35.91 | $45k | 40,474 | Apr 2, 2025 |
| Mar 10, 2025 | SRPT Sarepta Therapeutics, Inc. | AGrant or award Common Stock | +2,383 | - | - | 5,225 | Mar 11, 2025 |
| Mar 10, 2025 | SRPT Sarepta Therapeutics, Inc. | AGrant or award Stock Options (right to buy)derivative | +4,792 | $0.00 | $0 | 4,792 | Mar 11, 2025 |
| Dec 31, 2024 | LNC LINCOLN NATIONAL CORP | AGrant or award Phantom Stock Unitderivative | +1,419 | $31.71 | $45k | 38,707 | Jan 2, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.